



The Lilly TB Drug Discovery Initiative Facts at a Glance

What: The Lilly TB Drug Discovery Initiative is a nonprofit public-private partnership with a mission to accelerate early-stage drug discovery for tuberculosis (TB) by bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries in search of new TB treatments. Its primary goal is to fill the pipeline with new clinical candidates for future drug development in TB.

Why: Throughout the world, 1.5 million people (one every 15 seconds) die each year from TB. People think of TB as a disease of the past, but without the right treatment, TB will be a disease of the future right here at home. To fight the new strains we urgently need drugs with more muscle.

Who: The Initiative's members are Eli Lilly and Company, the Infectious Disease Research Institute (IDRI), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The Initiative is collaborating with Jubilant Biosys of Bangalore, India; Merck and Company in the U.S.; Seattle Biomedical Research Institute; YourEncore; Microbial Chemistry Research Foundation (MCRF) of Tokyo; and Summit plc of Oxfordshire, UK. In addition, the University of Washington's Department of Global Health is leading a monthly lecture series on Global Health and an annual Symposium on TB Drug Discovery.

Where: It is headquartered in Seattle, Washington.

When: The Initiative was announced in June, 2007. The organization officially launched in October, 2008, including the opening of laboratories, the first acquisition of compounds, the commencement of work and the first meeting of the Board of Advisors and Scientific Steering Committee.

Overview of the Organization

Employees: When fully staffed, it is anticipated that the organization will have up to 25 full-time, highly-skilled drug researchers on site in Seattle.

Expertise: The Initiative functions as a catalyst drawing together microbiologists, molecular biologists, synthetic chemists, medicinal chemists, pharmacologists, toxicologists, and process chemists to expedite the testing and optimizing of compounds for development. They come from government, academia, not-for-profit organizations and the pharmaceutical industry to create a truly "industrial strength" team.

Board of Advisors:

- Dr. Barry Bloom, Dean of Harvard University School of Public Health
- Dr. Queta Bond, President of Burroughs Wellcome Fund (ret.)
- Dr. Bruce Carter, Liaison to the Board of Directors for the TB Alliance
- Dr. Gail Cassell, Vice President, Scientific Affairs and Distinguished Research Scholar for Infectious Diseases at Lilly
- Dr. Paul Farmer, Founder and Executive Director of Partners in Health and Vice Chair of Department of Social Medicine at Harvard Medical School



The Lilly TB Drug Discovery Initiative

- Dr. Carole Heilman, Director of the Division of Microbiology and Infectious Diseases (DMID) at the NIAID, NIH
- Dr. Regina Rabinovitch, Director of Infectious Diseases for the Bill and Melinda Gates Foundation
- Dr. Barbara Laughon, Senior Scientist for TB Drug Development Partnerships in the Office of the Director, DMID, NIAID, NIH - Executive Secretary
- Dr. Steve Reed, Founder and Scientific Director of IDRI - Chair
- Dr. George Whitesides, Woodford L. and Ann A. Flowers University Professor at Harvard University

Scientific Steering Committee:

- Dr. Rachel Behrman, Deputy Director, Office of Medical Policy, Center for Drug Evaluation and Research at the Food and Drug Administration
- Dr. Patrick Brennan, Distinguished Professor, Department of Microbiology, Immunology and Pathology at Colorado State University
- Dr. Gail Cassell, Vice President, Scientific Affairs and Distinguished Research Scholar for Infectious Diseases at Lilly - Chair
- Dr. Richard Chaisson, Professor of Medicine, Epidemiology and International Health at Johns Hopkins University
- Dr. Stewart Cole, Professor of Microbial Pathogenesis at Ecole Polytechnique Federale de Lausanne, School of Life Sciences
- Dr. Andrew Dahlem, Vice President and Chief Operations Officer of Lilly Research Laboratories
- Dr. Jacques Grosset, Professor, Center for Tuberculosis Research at Johns Hopkins University
- Dr. Barbara Laughon, Senior Scientist for TB Drug Development Partnerships in the Office of the Director, DMID, NIAID, NIH - Executive Secretary
- Dr. Zhenkun Ma, Head of Research at the Global Alliance for TB Drug Development
- Dr. Carl Nathan, Professor and Chair of Department Microbiology and Immunology at Weill Medical College at Cornell Medical School
- Dr. Alan Palkowitz, Vice President of Discovery Chemistry Research and Technologies at Lilly
- Dr. Christine Sizemore, Chief of the Tuberculosis and other Mycobacterial Diseases Section at DMID, NIAID, NIH
- Dr. Ken Tanaka, Vice President of Research and Development at Paratek Pharmaceuticals
- Dr. Paul Wender, Bergstrom Professor of Chemistry at Stanford University

Financials: Lilly has given \$15 million to establish The Lilly TB Drug Discovery Initiative. Included in the donation is \$9 million in-kind, including fully equipped high throughput screening and chemistry laboratories, research tools, databases, and scientific and technical expertise, plus \$6 million in cash over five years to seed the organization. The Initiative will seek grants and contracts for additional funding with the ultimate goal of becoming self-sustaining. Any profits from research would be returned to the not-for-profit Lilly TB Drug Discovery Initiative.